

In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using *Mycobacterium tuberculosis* isolates

Nanda Hemvani, Vikas Patidar & D.S. Chitnis

Department of Microbiology, Immunology & Molecular Biology, Choithram Hospital & Research Centre, Indore, India

Received March 1, 2011

Background & objectives: Multiple drug resistance (MDR) among *Mycobacterium tuberculosis* poses a serious therapeutic problem. Early detection of MDR can be valuable but the conventional drug susceptibility tests take 4-6 wk time after the laboratory isolation of *M. tuberculosis*. The bacterial phage assay has been reported as a rapid tool for rifampicin susceptibility testing of tubercle bacilli using the suspension of isolated cultures. The present study was aimed to set up a phage assay for testing drug susceptibility to isoniazid (INH), rifampicin, ethambutol, streptomycin and ciprofloxacin in *M. tuberculosis* isolates.

Methods: Mueller-Hinton broth instead of Middle Brook 7H9 broth was used to make it more economical. The phage assay was compared with the proportion method using 100 *M. tuberculosis* isolates from pulmonary TB cases. Phage assay results were available in 48 h for rifampicin and streptomycin while 72 h required for INH, ethambutol and ciprofloxacin. The assay was compared with gold standard proportion method. Interpretation of the results was easy and clear.

Results: In the present study, sensitivity and specificity of the phage assay when compared to proportion method were in the range of 97 to 100 per cent for all the drugs except for ciprofloxacin for which it was 93 and 96 per cent, respectively.

Interpretation & conclusions: The phage assay was economic, easy to perform and rapid for the detection of drug resistance in *M. tuberculosis* isolates with no requirement of expensive equipment. It is within the reach of microbiology laboratories in developing countries having high loads of tuberculosis.

Key words Drug resistance - mycobacteriophage - MDR - sensitivity - specificity - tuberculosis

The emergence of multidrug-resistant tuberculosis (MDR-TB) and, more recently, extensively drug-resistant TB (XDR-TB) is a major threat to global TB control programmes^{1,2}.

Multi drug-resistant tuberculosis (MDR-TB), caused by isolates resistant to at least isoniazid (INH) and rifampicin, forms an alarming problem for the successful management of tuberculosis³. The

prevalence rate of MDR-TB in India is around 3 per cent among new cases, 12 per cent among pretreatment cases⁴ and an alarming 17 per cent among patients who have been treated earlier and developed multi-drug resistance (MDR). MDR-TB⁴ has been reported from almost all parts of the world, primarily as a consequence of poor and irregular treatment services, resulting into increased costs towards treatment and also increased risk of transmission of these resistant strains of the bacilli.

Rapid detection of MDR-TB can help in the effective management of such cases. The DOT plus programme is being geared up in India and other countries with high loads of TB⁵. However, the current phenotypic methods of assessing drug susceptibility for *Mycobacterium tuberculosis* are slow and take 4-6 wk after laboratory isolation of the organisms. Rapid methods based on polymerase chain reaction (PCR) are considered as alternative approach for the detection of MDR but detection of only rifampicin resistance through *rpoB* gene mutation⁶⁻⁹ has gained confidence, while in case of INH variations in resistance gene pose a problem. Mycobacteriophage-based techniques have also been reported for detection of viable bacilli in clinical specimens^{10,11} as well as for antimicrobial susceptibility testing¹²⁻²².

The mycobacteriophage-based assays depend upon the ability of resistant mycobacteria to support phage replication after being exposed to drugs, while sensitive bacilli get inactivated and hence are not able to support phage infection. Extracellular phages are inactivated with a virucidal agent, whereas intracellular phages are protected and replicate, causing their lysis and the release of a new phage progeny detected by the production of plaques on a fast-growing *M. smegmatis* (indicator strain) lawn. The released phages can be visualized on indicator plates as clear areas (plaques) within a lawn of fast growing *M. smegmatis*¹². This ingenious method does not require specialized laboratory skills or sophisticated equipment.

The aim of the present study was to set up a phage assay for drug susceptibility to isoniazid, rifampicin, ethambutol, streptomycin and ciprofloxacin using suspension of *M. tuberculosis* isolates and to compare it with proportion method.

Material & Methods

Mycobacterium isolates: A total of 100 consecutive *M. tuberculosis* isolates from respiratory samples of pulmonary tuberculosis cases referred to Microbiology

Department of Choithram Hospital and Research Centre (CHRC), Indore, India, during January 2009 to September 2010 were included in the study. The study protocol was approved by the Research and Ethical Committee of CHRC, Indore. The standard strain of *M. tuberculosis* H₃₇Rv, and *M. tuberculosis* wild isolates resistant to the drugs and maintained in the laboratory were used for quality control of every batch. *M. tuberculosis* was identified by using standard biochemical tests²³ and 3-4 wk old culture on Lowenstein-Jensen Medium (LJ) was used for making suspensions for the drug susceptibility tests.

Standardization of phage assay: Extensive standardization work was carried out to optimize the following conditions: liquid medium for cultivation of *M. smegmatis*; evaluation of various solid media for phage assay; inoculum size *M. smegmatis* for indicator plate; density of *M. tuberculosis* suspension; cut-off for plaque counts for sensitive and resistant *M. tuberculosis*; optimal concentration of drugs for exposure to *M. tuberculosis*; drug exposure time for *M. tuberculosis*; and concentration and exposure time period of ferrous ammonium sulphate (FAS) for killing extracellular phages.

Adequate controls replicated were included for the standardization work to fix up the optimal conditions.

Phage assay protocol for drug susceptibility testing: The suspension of *M. tuberculosis* isolates was prepared in Muller-Hinton (M-H) broth in plastic tubes containing 8-10 glass beads. The inoculum was adjusted to McFarland tube No.1. INH, ethambutol and streptomycin (Sigma-Aldrich Chemicals GmbH, Steinheim, Germany) stock solutions (10 mg/10 ml) were made in distilled water and filtered through 0.2 µ pore size membrane. Rifampicin and ciprofloxacin stock solutions were made in dimethyl formamide (Sigma, USA). All stock solutions were aliquoted and preserved at -70°C till use.

Working solution was prepared in M-H broth (B.D. Difco, USA) The drug concentrations used were: INH (0.4 µg/ml), rifampicin (2 µg/ml), ethambutol (16 µg/ml), streptomycin (2 µg/ml), and ciprofloxacin (4 µg/ml). Plain M-H broth without drug served as control.

M-H agar supplemented with 0.4 per cent glycerol and 1 per cent glucose was used for plate pouring in phage assay. *M. smegmatis* mc²155 strain was used for propagation of mycobacteriophages on M-H agar. Mycobacteriophage (D29) was propagated on *M. smegmatis*, as described earlier²⁴. The supernatant

containing phages was passed through 0.22 μ Millipore filter membrane and stored at -20°C . The phage titre was determined using a standard spot test²⁴.

M. tuberculosis isolates were exposed to rifampicin for 24 h while exposure time for other drugs was 48 h (based on our preliminary work and other studies)¹¹⁻²¹. The concentrations of the drugs used for phage assay were also based on our preliminary study (unpublished). The assay was carried out in 10 ml plastic screw capped tubes (Nunc, USA). Five hundred microlitre of *M. tuberculosis* suspension was mixed with 500 μl drug. Wild drug resistant strains (laboratory isolates) and *M. tuberculosis* H₃₇Rv were included in all batches. The tubes were incubated for 24/48 h at 37°C .

Mycobacteriophage D29 (200 μl , 10^8 pfu /ml) was added into the respective tubes and incubated for 90 min at 37°C . The extracellular phages were inactivated with 200 μl of phagocidal agent ferrous ammonium sulphate (working concentration 30mM) (Merck, India) with contact time of 10 min. The contents of the tubes were transferred to 10 ml M-H broth in 18×150 mm tube and vortexed. One ml of the broth mixture and 1 ml of *M. smegmatis* suspension were dispensed in sterile disposable Petri dish (90 mm); and 10 ml of molten M-H agar supplemented with glycerol and glucose was added and mixed by rotating clock-wise and anti clock-wise. The plates were left for 10 min for solidification and transferred to incubator at 37°C for over night. Results were analyzed by counting the plaques. In control plates the plaque count ranged from 90-150 on plate. The isolates were considered resistant if reduction in plaque count was less than 80 per cent compared to control plate, and susceptible if more than 80 per cent reduction was observed.

Drug susceptibility testing by proportion method: The proportion method²⁵ was carried out using L-J medium. The recommended critical concentrations²⁵ of INH 0.2 $\mu\text{g}/\text{ml}$, rifampicin 40 $\mu\text{g}/\text{ml}$, ethambutol 2 $\mu\text{g}/\text{ml}$, streptomycin 4 $\mu\text{g}/\text{ml}$ and ciprofloxacin 2 $\mu\text{g}/\text{ml}$ were used. The first reading was taken after 28 days of

incubation and the second on 42nd day. The percentage resistance (R) was calculated as the ratio of the number of colonies on the drug containing media to those on the control medium.

Statistical analysis: Data were analysed using Bayes-Theorem, 2×2 contingency tables to calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) using StatsDirect statistical software version 2.7.2, UK. McNemar's test was applied using Graphpad software Inc., USA (two tailed pair test) where each isolate was matched for phage assay and proportion method.

Results

Of the 100 *M. tuberculosis* isolates tested, 58 (58%) were resistant to INH, 43 to rifampicin, 55 isolates streptomycin, 32 to ethambutol and 28 isolates were resistant to ciprofloxacin by proportion method. Forty isolates were resistant to both rifampicin and INH (*i.e.* MDR) by proportion method.

When phage assay was compared with proportion method, 57 of 58 INH resistant isolates and 41 of the 42 sensitive isolates were correctly identified by the phage assay (Table). Discordance for phage assay was seen among only two isolates. The sensitivity of the mycobacteriophage assay in detecting INH resistance was 98 per cent; and the specificity achieved was also 98 per cent. Both positive and negative predictive values were 98 per cent.

In case of rifampicin, both resistant and sensitive isolates were correctly identified by the phage assay. The sensitivity of the mycobacteriophage assay in detecting rifampicin resistance was 100 per cent; and the specificity achieved was also 100 per cent. Positive and negative predictive values were also 100 per cent for both. The sensitivity and specificity for ethambutol were 97 per cent for both. Positive and negative predictive values were 94 and 99 per cent, respectively. The sensitivity and specificity for ciprofloxacin were 93 and 96 per cent, respectively. The positive and negative

Table. Comparison of phage and proportion methods for determining sensitivity of *M. tuberculosis*

Term	Proportion method	Phage method	Isoniazid	Rifampicin	Streptomycin	Ethambutol	Ciprofloxacin
A	Resistant	Resistant	57	43	54	31	26
B	Sensitive	Sensitive	41	57	45	66	69
C	Resistant	Sensitive	1	0	1	1	2
D	Sensitive	Resistant	1	0	0	2	3

A + C, total resistant by proportion method; A + D, total resistant by phage method

predictive values were 90 and 97 per cent, respectively. Each isolate was checked for drug sensitivity by both conventional proportion method and phage assay and thus, matched pairs were formed to allow McNemar's test.

Discussion

The phage based assay was developed by Wilson and colleagues²², and was applied to rifampicin and isoniazid susceptibility testing for clinical isolates of *M. tuberculosis*. The commercial phage assay is available only for detection of resistance for rifampicin^{26,27}. Hence, the present study was aimed to standardize in-house phage assay for all the first line anti-TB drug resistance detection. Fluoroquinolones are widely used along with other anti-TB drugs and therefore, were also included in the present study.

Middle brook 7H9 medium was replaced with Mueller Hinton broth to make the assay economical. The cost of the commercial phage assay (FASTPlaque TB-RIF, Biotec Laboratories Ltd, UK) for rifampicin resistance is over ₹ 500 per test while the cost of consumables for in-house phage based assay was less than ₹50 per drug per isolate.

In the present study, sensitivity and specificity of the phage assay when compared to proportion method were in the range of 97 to 100 per cent and for ciprofloxacin it was 93 and 96 per cent, respectively. The data on positive and negative predictive values, favoured the utility of the in-house phage assay.

Reduction in plaque count >80 per cent was considered as susceptible to the drug in the present study. However, in case of rifampicin and streptomycin susceptible isolates, more than 99 per cent reduction in plaque count was observed. This appeared to be due to high and rapid bactericidal activity of the drugs for *Mycobacterium*. Another mycobacteriophage-based assay, the luciferase reporter phage (LRP) assay showed a 99 per cent reduction in the light signal after an overnight incubation of susceptible isolates with streptomycin²⁸. These two drugs required shorter time exposure (24 h) compared to other drugs which required 48 h exposure as observed in the other study¹⁹. The mode of action of the drug may also be a contributory factor, e.g. activity at transcription/translation level (streptomycin, rifampicin) and at cell wall level (INH, ethambutol)²⁹.

Our findings were comparable with other studies for rifampicin^{14,15,17,20,30}, INH and or streptomycin^{12,16,18,21}.

In case of fluoroquinolones, only two studies reported phage assay^{12,31}, and information is scanty for ethambutol¹¹.

Molecular methods have limitations since the PCR is directed towards the particular mutant. Such difficulty does not arise for phage based assays since these are dependent on the viability following drug exposure.

The drug resistance determination on direct clinical samples such as sputum will be of immense value, since it will bring down the reporting time to 2-3 days on the direct samples.

In conclusion, the in-house phage assay standardized for detection of drug resistance in *M. tuberculosis* culture suspension showed high sensitivity and specificity and the results were available within 2-3 days. The assay was economical and within the reach of microbiology laboratories in developing countries. Overall concordance with proportion method was good.

Acknowledgment

This work was supported by young scientist scheme grant SR/FT/L-116/2006 from DST (Department of Science and Technology), New Delhi, India.

References

1. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion MC. Multidrug-resistant and extensively drug-resistant *Mycobacterium tuberculosis*: epidemiology and control. *Expert Rev Anti Infect Ther* 2007; 5 : 857-71.
2. Shah N, Wright A, Bai GH, Barrera L, Boulahbal F, Martan-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis* 2007; 13 : 380-7.
3. Yew WW, Chau CH. Drug-resistant tuberculosis in the 1990s. *Eur Respir J* 1995; 8 : 1184-92.
4. World Health Organization. *Global tuberculosis control: epidemiology, strategy, financing: WHO Report 2009*. (WHO/HTM/TB/2009.411). Geneva: World Health Organization; 2009.
5. Gupta R, Espinal M, Stop TB Working Group on DOTSPPlus for MDR-TB. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDRTB). *Int J Tuberc Lung Dis* 2003; 7 : 410-4.
6. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, et al. Contribution of *rpoB* mutations to development of rifamycin cross-resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1998; 42 : 1853-7.
7. Williams DL, Spring L, Gillis TP, Salfinger M, Persing DH. Evaluation of a polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampin susceptibility of *Mycobacterium tuberculosis* from sputum specimens. *Clin Infect Dis* 1998; 26 : 446-50.

8. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, *et al.* Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* 1993; 341 : 647-50.
9. Garcia L, Alonso-Sanz M, Rebollo MJ, Tercero JC, Chaves F. Mutations in the *rpoB* gene of rifampin-resistant *Mycobacterium tuberculosis* isolates in Spain and their rapid detection by PCR-enzyme-linked immunosorbent assay. *J Clin Microbiol* 2001; 39 : 1813-8.
10. Park DJ, Drobniewski FA, Meyer A, Wilson SM. Use of a phage-based assay for phenotypic detection of mycobacteria directly from sputum. *J Clin Microbiol* 2003; 41 : 680-8.
11. Barman P, Gadre DA. Study of phage based diagnostic technique for tuberculosis. *Indian J Tuberc* 2007; 54 : 36-40.
12. Eltringham IJ, Wilson SM, Drobniewski FA. Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1999; 37 : 3528-32.
13. Gali' N, Dominguez J, Blanco S, Prat C, Alcaide F, Coll P, *et al.* Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of *Mycobacterium tuberculosis* isolates to isoniazid and influence of resistance level on assay performance. *J Clin Microbiol* 2006; 44 : 201-5.
14. Gali N, Dominguez J, Blanco S, Prat C, Quesada MD, Matas L, *et al.* Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in *Mycobacterium tuberculosis* clinical isolates. *J Clin Microbiol* 2003; 41 : 2647-9.
15. Yzquierdo SL, Lemus D, Echemendia M, Montoro E, McNerney R, Martin A, *et al.* Evaluation of phage assay for rapid phenotypic detection of rifampicin resistance in *Mycobacterium tuberculosis*. *Ann Clin Microbiol Antimicrob* 2006; 5 : 5-11.
16. Chauca JA, Palomino JC, Guerra H. Evaluation of rifampicin and isoniazid susceptibility testing of *Mycobacterium tuberculosis* by a mycobacteriophage D29-based assay. *J Med Microbiol* 2007; 56 : 360-4.
17. Traore H, Ogwang S, Mallard K, Joloba ML, Mumbowa F, Narayan K, *et al.* Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. *Ann Clin Microbiol Antimicrob* 2007; 6 : 1.
18. Da Silva PA, Boffo MMS, de Mattos IG, Silva AB, Palomino JC, Martin A, *et al.* Comparison of redox and D29 phage methods for detection of isoniazid and rifampicin resistance in *Mycobacterium tuberculosis*. *Clin Microbiol Infect* 2006; 12 : 293-6.
19. Eltringham IJ, Drobniewski FA, Mangan JA, Butcher PD, Wilson SM. Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1999; 37 : 3524-7.
20. McNerney R, Mallard K, Urassa HM, Lemma E, Donoghue HD. Colorimetric phage-based assay for detection of rifampin-resistant *Mycobacterium tuberculosis*. *J Clin Microbiol* 2007; 45 : 1330-2.
21. McNerney R, Kiepiela P, Bishop K, Nye PM, Stoker NG. Rapid screening of *Mycobacterium tuberculosis* for susceptibility to rifampicin and streptomycin. *Int J Tuberc Lung Dis* 2000; 4 : 69-75.
22. Wilson SM, Al-Suwaidi Z, McNerney R, Porter J, Drobniewski FA. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of *Mycobacterium tuberculosis*. *Nat Med* 1997; 3 : 465-8.
23. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn EC Jr, editors. *Color atlas and textbook of diagnostic microbiology*, 5th ed. Philadelphia: JB Lippincott; 1997.
24. Sarkis JS, Hatfull GF. Mycobacteriophages. *Methods Mol Biol* 1998; 101 : 145-73.
25. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, *et al.* Mycobacteria: laboratory methods for testing drug sensitivity and resistance. *Bull World Health Organ* 1963; 29 : 565-78.
26. Albert H, Heydenrych A, Mole R, Trollip A, Blumberg L. Evaluation of FASTPlaque TB-RIF, a rapid, manual test for the determination of rifampicin resistance from *Mycobacterium tuberculosis* cultures. *Int J Tuberc Lung Dis* 2001; 5 : 906-11.
27. Albert H, Trollip A, Seaman T, Mole RJ. Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of *Mycobacterium tuberculosis* directly from sputum. *Int J Tuberc Lung Dis* 2004; 8 : 1114-9.
28. Riska PF, Jacobs WR Jr. The use of luciferase-reporter phage for antibiotic-susceptibility testing of mycobacteria. *Methods Mol Biol* 1998; 101 : 431-55.
29. Jacobs WR Jr, Barletta RG, Udani R, Chan J, Kalkut G, Sosne G, *et al.* Rapid assessment of drug susceptibilities of *Mycobacterium tuberculosis* by means of luciferase reporter phages. *Science* 1993; 260 : 819-22.
30. Simboli N, Takiff H, McNerney R, Lopez B, Martin A, Palomino JC, *et al.* In-house phage amplification assay is a sound alternative for detecting rifampin-resistant *Mycobacterium tuberculosis* in low-resource settings. *Antimicrob Agents Chemother* 2005; 49 : 425-7.
31. Stella EJ, de la Iglesia AI, Morbidoni HR. Comparison of the performance of two mycobacteriophage D29-based protocols for fluoroquinolone susceptibility testing in *Mycobacterium tuberculosis*. *J Microbiol Methods* 2009; 79 : 371-3.

Reprint requests: Dr D.S. Chitnis, Department of Microbiology, Immunology & Molecular biology, Intermediate Referral Laboratory for Mycobacteriology, Choithram Hospital & Research Centre, Manik Bagh Road, Indore 452 014, India
e-mail: ds_chitnis@rediffmail.com